Showing 4601-4610 of 9940 results for "".
- FDA Clears Syneron Candela's UltraShape Power for Fat Destructionhttps://practicaldermatology.com/news/fda-clears-syneron-candelas-ultrashape-power-for-fat-destruction/2458499/The FDA cleared Syneron Medical Ltd.'s non-invasive fat destruction device, UltraShape Power. for non-invasive reduction of abdominal circumference via fat cell destruction. UltraShape Power uses focused, pulsed mechanical ultrasound energy to target and destroy fat, offering measurab
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),
- Dermatologist Swaps His Scalpel for a Penhttps://practicaldermatology.com/news/dermatologist-swaps-his-scalpel-for-a-pen/2458535/Steven M. Hacker, MD, a Delray Beach dermatologist and author, has released his debut novel. "The Caduceus and The Swastika". The thriller tells a frightening but endearing story of what happened to a group of medical students when Nazi's became medical professors and began a
- Solta Medical Launches Consumer Campaign to Empower LGBTQ Communityhttps://practicaldermatology.com/news/solta-medical-launches-consumer-campaign-to-empower-lgbtq-community/2458538/Solta Medical, a division of Valeant Pharmaceuticals North America LLC, is supporting the LGBTQ community through a focused consumer campaign that will help shed one more layer to reveal one’s true self. In addition, Solta Medical was the exclusive medical aesthetic category sponsor of the
- Dermira's DRM04 Shows Promise for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-drm04-shows-promise-for-primary-axillary-hyperhidrosis/2458543/Dermira’s DRM04 may help put the brakes on primary axillary hyperhidrosis, according to topline results from two Phase 3 trials. Based on the results of these trials, Dermira plans to submit a New Drug Application to the US Food and Drug Administ
- Sernivo Spray Hits Pharmacy Shelveshttps://practicaldermatology.com/news/sernivo-spray-hits-pharmacy-shelves/2458544/Sernivo™ Spray for psoriasis is officially available. Dr. Reddy’s Laboratories’ US subsidiary, Promius Pharma, LLC, U.S. Sernivo™ Spray (betamethasone dipropionate) 0.05% was approved by the Food and Drug Administration (F
- Dr. Brandt's Legacy Lives on with New Dr. Brandt® Skincare Advisory Boardhttps://practicaldermatology.com/news/dr-brandts-legacy-lives-on-with-new-dr-brandt-skincare-advisory-board/2458563/Dr. Brandt® Skincare is rolling out a new Advisory Board to elevate the brand and honor Dr. Brandt’s legacy of innovation in dermatology. Frederick Brandt died on April 5, 2015 in his home in Coconut Grove, Florida. The first
- Dove Survey: Life Without Deodorant Would Be the Pitshttps://practicaldermatology.com/news/dove-survey-life-without-deodorant-would-be-the-pits/2458566/And the winner is … deodorant. Out of all the products women use in their morning beauty routine, deodorant is what makes them feel most confident– it’s twice as significant as toothpaste, four times that of foundation, nearly six times that of mascara and ten tim
- Dermira's Novel Facial Acne Treatment Passes Muster in Phase 2b Studyhttps://practicaldermatology.com/news/dermiras-drm01-performs-well-in-facial-acne-study/2458571/Dermira’s novel topical sebum inhibitor -- DRMO1 -- may put the brakes on facial acne, according to topline results from a Phase 2b dose-ranging study that is paving the way toward a Phase 3 Clinical Program. DRM01 is a novel, small molecul
- Skin Cancer Expert Perry Robins, MD Joins Emerald's Advisory Boardhttps://practicaldermatology.com/news/skin-cancer-expert-perry-robins-md-joins-emeralds-advisory-board/2458574/New York City dermatologist Perry Robins, MD has joined Emerald Medical Applications Corp.’s advisory board. Emerald, an Israeli-based company, is developing DermaCompare™, a proprietary artificial intelligence free app